Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1α/OATPs signaling axis

Biomaterials

Volumn 35, Issue 28, 2014, Pages 8175-8185

  Wu, Jason Boyang ^a   Shao, Chen ^a,b   Li, Xiangyan ^a   Shi, Changhong ^a,c   Li, Qinlong ^a   Hu, Peizhen ^a   Chen, Yi Ting ^a   Dou, Xiaoliang ^b   Sahu, Divya ^d   Li, Wei ^d   Harada, Hiroshi ^e   Zhang, Yi ^a   Wang, Ruoxiang ^a   Zhau, Haiyen E ^a   Chung, Leland W K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer imaging; HIF1 ; Hypoxia; Near infrared dyes; Organic anion transporting polypeptides

Indexed keywords

DIAGNOSIS; FLUORESCENCE; INFRARED DEVICES; MEDICAL IMAGING; TUMORS;

CANCER IMAGING; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; MECHANISTIC PROPERTIES; MICROARRAY ANALYSIS; NEAR-INFRARED DYES; NEAR-INFRARED FLUORESCENCE; NEAR-INFRARED FLUORESCENCE IMAGING;

DISEASES;

CARBOCYANINE; DYE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ORGANIC ANION TRANSPORTER; COLORING AGENT; CONTRAST MEDIUM; HIF1A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL LINE; CONTROLLED STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR XENOGRAFT; UROGENITAL TRACT CANCER; ANIMAL; ANOXIA; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE COURSE; DNA MICROARRAY; FLUORESCENCE MICROSCOPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; NEAR INFRARED SPECTROSCOPY; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANOXIA; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COLORING AGENTS; CONTRAST MEDIA; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SPECTROSCOPY, NEAR-INFRARED;

EID: 84903709154     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.073     Document Type: Article

References (50)

1. Wu J., Pan D., Chung L.W. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer. Transl Androl Urol 2014, 2:254-264.
2. Frangioni J.V. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7:626-634.
3. Rao J., Dragulescu-Andrasi A., Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 2007, 18:17-25.
4. Hawrysz D.J., Sevick-Muraca E.M. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2000, 2:388-417.
5. Hintersteiner M., Enz A., Frey P., Jaton A.L., Kinzy W., Kneuer R., et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005, 23:577-583.
6. Wu X., Liu H., Liu J., Haley K.N., Treadway J.A., Larson J.P., et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003, 21:41-46.
7. Humblet V., Lapidus R., Williams L.R., Tsukamoto T., Rojas C., Majer P., et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005, 4:448-462.
8. Frangioni J.V. New technologies for human cancer imaging. J Clin Oncol 2008, 26:4012-4021.
9. Pierce M.C., Javier D.J., Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer 2008, 123:1979-1990.
10. Edwards P.A. Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. Br J Cancer 1985, 51:149-160.
11. Yang X., Shi C., Tong R., Qian W., Zhau H.E., Wang R., et al. Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res 2010, 16:2833-2844.
12. Yang X., Shao C., Wang R., Chu C.Y., Hu P., Master V., et al. Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. J Urol 2013, 189:702-710.
13. Zhau H.Y., Chang S.M., Chen B.Q., Wang Y., Zhang H., Kao C., et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A 1996, 93:15152-15157.
14. Zhau H.E., Odero-Marah V., Lue H.W., Nomura T., Wang R., Chu G., et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 2008, 25:601-610.
15. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994, 57:406-412.
16. Qi J., Tripathi M., Mishra R., Sahgal N., Fazli L., Ettinger S., et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013, 23:332-346.
17. Wu J.B., Chen K., Li Y., Lau Y.F., Shih J.C. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J 2009, 23:4029-4038.
18. Sahu D., Zhao Z., Tsen F., Cheng C.F., Park R., Situ A.J., et al. A potentially common peptide target in secreted heat shock protein-90alpha for hypoxia-inducible factor-1alpha-positive tumors. Mol Biol Cell 2012, 23:602-613.
19. Hu P., Chu G.C., Zhu G., Yang H., Luthringer D., Prins G., et al. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One 2011, 6:e28670.
20. Chen K., Ou X.M., Wu J.B., Shih J.C. Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol Pharmacol 2011, 79:308-317.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
22. Wu J.B., Chen K., Ou X.M., Shih J.C. Retinoic acid activates monoamine oxidase B promoter in human neuronal cells. J Biol Chem 2009, 284:16723-16735.
23. Wu J.B., Shih J.C. Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol Pharmacol 2011, 80:714-723.
24. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
25. Ameri K., Luong R., Zhang H., Powell A.A., Montgomery K.D., Espinosa I., et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010, 102:561-569.
26. Harada H., Kizaka-Kondoh S., Itasaka S., Shibuya K., Morinibu A., Shinomiya K., et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007, 360:791-796.
27. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
28. Li J., Shi M., Cao Y., Yuan W., Pang T., Li B., et al. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 2006, 342:1341-1351.
29. Obaidat A., Roth M., Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012, 52:135-151.
30. Pressler H., Sissung T.M., Venzon D., Price D.K., Figg W.D. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011, 6:e20372.
31. Yang M., Xie W., Mostaghel E., Nakabayashi M., Werner L., Sun T., et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011, 29:2565-2573.
32. Semenza G.L., Agani F., Booth G., Forsythe J., Iyer N., Jiang B.H., et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997, 51:553-555.
33. Zbar B., Klausner R., Linehan W.M. Studying cancer families to identify kidney cancer genes. Annu Rev Med 2003, 54:217-233.
34. Hirche C., Murawa D., Mohr Z., Kneif S., Hunerbein M. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 2010, 121:373-378.
35. Cherrick G.R., Stein S.W., Leevy C.M., Davidson C.S. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960, 39:592-600.
36. Kosaka N., Mitsunaga M., Longmire M.R., Choyke P.L., Kobayashi H. Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. Int J Cancer 2011, 129:1671-1677.
37. Less J.R., Skalak T.C., Sevick E.M., Jain R.K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991, 51:265-273.
38. Jin H., Kang K.A. Fluorescence-mediated detection of a heterogeneity in a highly scattering media. Adv Exp Med Biol 2005, 566:167-172.
39. Hamada A., Sissung T., Price D.K., Danesi R., Chau C.H., Sharifi N., et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008, 14:3312-3318.
40. Ihmels H., Thomas L. Light up G-quadruplex DNA with a [2.2.2]heptamethinecyanine dye. Org Biomol Chem 2013, 11:480-487.
41. Karlsson H.J., Eriksson M., Perzon E., Akerman B., Lincoln P., Westman G. Groove-binding unsymmetrical cyanine dyes for staining of DNA: syntheses and characterization of the DNA-binding. Nucleic Acids Res 2003, 31:6227-6234.
42. Volkova K.D., Kovalska V.B., Balanda A.O., Vermeij R.J., Subramaniam V., Slominskii Y.L., et al. Cyanine dye-protein interactions: looking for fluorescent probes for amyloid structures. J Biochem Biophys Methods 2007, 70:727-733.
43. Patonay G., Kim J.S., Kodagahally R., Strekowski L. Spectroscopic study of a novel bis(heptamethine cyanine) dye and its interaction with human serum albumin. Appl Spectrosc 2005, 59:682-690.
44. Yeh C.S., Su C.H., Ho W.Y., Huang C.C., Chang J.C., Chien Y.H., et al. Tumor targeting and MR imaging with lipophilic cyanine-mediated near-infrared responsive porous Gd silicate nanoparticles. Biomaterials 2013, 34:5677-5688.
45. Henary M., Pannu V., Owens E.A., Aneja R. Near infrared active heptacyanine dyes with unique cancer-imaging and cytotoxic properties. Bioorg Med Chem Lett 2012, 22:1242-1246.
46. Zhang Y., Xiao L., Popovic K., Xie X., Chordia M.D., Chung L.W., et al. Novel cancer-targeting SPECT/NIRF dual-modality imaging probe (99m)Tc-PC-1007: synthesis and biological evaluation. Bioorg Med Chem Lett 2013, 23:6350-6354.
47. Xiao L., Zhang Y., Yue W., Xie X., Wang J.P., Chordia M.D., et al. Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation. Nucl Med Biol 2013, 40:351-360.
48. Tan X., Luo S., Wang D., Su Y., Cheng T., Shi C. A NIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Biomaterials 2012, 33:2230-2239.
49. Hulikova A., Harris A.L., Vaughan-Jones R.D., Swietach P. Regulation of intracellular pH in cancer cell lines under normoxia and hypoxia. J Cell Physiol 2013, 228:743-752.
50. Brahimi-Horn M.C., Pouyssegur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 2007, 43:165-178.